The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway

Kideok Jin, Xiangjun Kong, Tariq Shah, Marie-France Penet, Flonne Wildes, Dennis C. Sgroi, Xiao Jun Ma, Yi Huang, Anne Kallioniemi, Goran Landberg, Ivan Bieche, Xinyan Wu, Peter E. Lobie, Nancy E. Davidson, Zaver M Bhujwalla, Tao Zhu, Saraswati Sukumar

Research output: Contribution to journalArticle

Abstract

Multiple factors including long-term treatment with tamoxifen are involved in the development of selective estrogen receptor (ER) modulator resistance in ERα-positive breast cancer. Many underlying molecular events that confer resistance are known but a unifying theme is yet to be revealed. In this report, we provide evidence that HOXB7 overexpression renders MCF-7 cells resistant to tamoxifen via cross-talk between receptor tyrosine kinases and ERα signaling. HOXB7 is an ERα-responsive gene. Extended treatment of MCF-7 cells with tamoxifen resulted in progressively increasing levels of HOXB7 expression, along with EGFR and EGFR ligands. Up-regulation of EGFR occurs through direct binding of HOXB7 to the EGFR promoter, enhancing transcriptional activity. Finally, higher expression levels of HOXB7 in the tumor significantly correlated with poorer disease-free survival in ERα-positive patients with breast cancer on adjuvant tamoxifen monotherapy. These studies suggest that HOXB7 acts as a key regulator, orchestrating a major group of target molecules in the oncogenic hierarchy. Functional antagonism of HOXB7 could circumvent tamoxifen resistance.

Original languageEnglish (US)
Pages (from-to)2736-2741
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume109
Issue number8
DOIs
StatePublished - Feb 21 2012

Fingerprint

Tamoxifen
Estrogen Receptors
Breast Neoplasms
MCF-7 Cells
Proteins
Receptor Cross-Talk
Selective Estrogen Receptor Modulators
Receptor Protein-Tyrosine Kinases
Disease-Free Survival
Up-Regulation
Ligands
Therapeutics
Genes
Neoplasms

ASJC Scopus subject areas

  • General

Cite this

The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. / Jin, Kideok; Kong, Xiangjun; Shah, Tariq; Penet, Marie-France; Wildes, Flonne; Sgroi, Dennis C.; Ma, Xiao Jun; Huang, Yi; Kallioniemi, Anne; Landberg, Goran; Bieche, Ivan; Wu, Xinyan; Lobie, Peter E.; Davidson, Nancy E.; Bhujwalla, Zaver M; Zhu, Tao; Sukumar, Saraswati.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, No. 8, 21.02.2012, p. 2736-2741.

Research output: Contribution to journalArticle

Jin, K, Kong, X, Shah, T, Penet, M-F, Wildes, F, Sgroi, DC, Ma, XJ, Huang, Y, Kallioniemi, A, Landberg, G, Bieche, I, Wu, X, Lobie, PE, Davidson, NE, Bhujwalla, ZM, Zhu, T & Sukumar, S 2012, 'The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway', Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 8, pp. 2736-2741. https://doi.org/10.1073/pnas.1018859108
Jin, Kideok ; Kong, Xiangjun ; Shah, Tariq ; Penet, Marie-France ; Wildes, Flonne ; Sgroi, Dennis C. ; Ma, Xiao Jun ; Huang, Yi ; Kallioniemi, Anne ; Landberg, Goran ; Bieche, Ivan ; Wu, Xinyan ; Lobie, Peter E. ; Davidson, Nancy E. ; Bhujwalla, Zaver M ; Zhu, Tao ; Sukumar, Saraswati. / The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. In: Proceedings of the National Academy of Sciences of the United States of America. 2012 ; Vol. 109, No. 8. pp. 2736-2741.
@article{247cb31a4ee7471083afeb0966428185,
title = "The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway",
abstract = "Multiple factors including long-term treatment with tamoxifen are involved in the development of selective estrogen receptor (ER) modulator resistance in ERα-positive breast cancer. Many underlying molecular events that confer resistance are known but a unifying theme is yet to be revealed. In this report, we provide evidence that HOXB7 overexpression renders MCF-7 cells resistant to tamoxifen via cross-talk between receptor tyrosine kinases and ERα signaling. HOXB7 is an ERα-responsive gene. Extended treatment of MCF-7 cells with tamoxifen resulted in progressively increasing levels of HOXB7 expression, along with EGFR and EGFR ligands. Up-regulation of EGFR occurs through direct binding of HOXB7 to the EGFR promoter, enhancing transcriptional activity. Finally, higher expression levels of HOXB7 in the tumor significantly correlated with poorer disease-free survival in ERα-positive patients with breast cancer on adjuvant tamoxifen monotherapy. These studies suggest that HOXB7 acts as a key regulator, orchestrating a major group of target molecules in the oncogenic hierarchy. Functional antagonism of HOXB7 could circumvent tamoxifen resistance.",
author = "Kideok Jin and Xiangjun Kong and Tariq Shah and Marie-France Penet and Flonne Wildes and Sgroi, {Dennis C.} and Ma, {Xiao Jun} and Yi Huang and Anne Kallioniemi and Goran Landberg and Ivan Bieche and Xinyan Wu and Lobie, {Peter E.} and Davidson, {Nancy E.} and Bhujwalla, {Zaver M} and Tao Zhu and Saraswati Sukumar",
year = "2012",
month = "2",
day = "21",
doi = "10.1073/pnas.1018859108",
language = "English (US)",
volume = "109",
pages = "2736--2741",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "8",

}

TY - JOUR

T1 - The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway

AU - Jin, Kideok

AU - Kong, Xiangjun

AU - Shah, Tariq

AU - Penet, Marie-France

AU - Wildes, Flonne

AU - Sgroi, Dennis C.

AU - Ma, Xiao Jun

AU - Huang, Yi

AU - Kallioniemi, Anne

AU - Landberg, Goran

AU - Bieche, Ivan

AU - Wu, Xinyan

AU - Lobie, Peter E.

AU - Davidson, Nancy E.

AU - Bhujwalla, Zaver M

AU - Zhu, Tao

AU - Sukumar, Saraswati

PY - 2012/2/21

Y1 - 2012/2/21

N2 - Multiple factors including long-term treatment with tamoxifen are involved in the development of selective estrogen receptor (ER) modulator resistance in ERα-positive breast cancer. Many underlying molecular events that confer resistance are known but a unifying theme is yet to be revealed. In this report, we provide evidence that HOXB7 overexpression renders MCF-7 cells resistant to tamoxifen via cross-talk between receptor tyrosine kinases and ERα signaling. HOXB7 is an ERα-responsive gene. Extended treatment of MCF-7 cells with tamoxifen resulted in progressively increasing levels of HOXB7 expression, along with EGFR and EGFR ligands. Up-regulation of EGFR occurs through direct binding of HOXB7 to the EGFR promoter, enhancing transcriptional activity. Finally, higher expression levels of HOXB7 in the tumor significantly correlated with poorer disease-free survival in ERα-positive patients with breast cancer on adjuvant tamoxifen monotherapy. These studies suggest that HOXB7 acts as a key regulator, orchestrating a major group of target molecules in the oncogenic hierarchy. Functional antagonism of HOXB7 could circumvent tamoxifen resistance.

AB - Multiple factors including long-term treatment with tamoxifen are involved in the development of selective estrogen receptor (ER) modulator resistance in ERα-positive breast cancer. Many underlying molecular events that confer resistance are known but a unifying theme is yet to be revealed. In this report, we provide evidence that HOXB7 overexpression renders MCF-7 cells resistant to tamoxifen via cross-talk between receptor tyrosine kinases and ERα signaling. HOXB7 is an ERα-responsive gene. Extended treatment of MCF-7 cells with tamoxifen resulted in progressively increasing levels of HOXB7 expression, along with EGFR and EGFR ligands. Up-regulation of EGFR occurs through direct binding of HOXB7 to the EGFR promoter, enhancing transcriptional activity. Finally, higher expression levels of HOXB7 in the tumor significantly correlated with poorer disease-free survival in ERα-positive patients with breast cancer on adjuvant tamoxifen monotherapy. These studies suggest that HOXB7 acts as a key regulator, orchestrating a major group of target molecules in the oncogenic hierarchy. Functional antagonism of HOXB7 could circumvent tamoxifen resistance.

UR - http://www.scopus.com/inward/record.url?scp=84863115448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863115448&partnerID=8YFLogxK

U2 - 10.1073/pnas.1018859108

DO - 10.1073/pnas.1018859108

M3 - Article

VL - 109

SP - 2736

EP - 2741

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 8

ER -